Genetic Tweaks to Tuberculosis Could Speed Up Discovery of a New Vaccine
August 21, 2017
(STAT News) – The only existing tuberculosis vaccine — known as Bacille Calmette-Guérin (BCG) — contains a weakened bacterium that is a different cousin of Mycobacterium tuberculosis. And while the vaccine is 60 to 80 percent effective in children, it works poorly in adults. Partly for that reason, while BCG is widely administered in many parts of the world, it’s not used in the United States. Multiple other vaccine candidates are currently moving through clinical trials, with some encouraging early results. A better vaccine could save lives on a stunning scale. Annually, tuberculosis kills more people than HIV or malaria, though the number of deaths has fallen over time.